Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Small cell lung cancer (SCLC) remains a challenging diagnosis with limited treatment options.
• Interferon-alpha (IFN-alpha) has been explored as an adjunct therapy in various cancers.
• Investigating the efficacy and safety of concomitant chemotherapy and IFN-alpha in SCLC is crucial.

Purpose of the Study:

• To evaluate the impact of adding low-dose interferon-alpha (IFN-alpha) to standard chemotherapy on survival in small cell lung cancer patients.
• To compare the outcomes of chemotherapy alone versus chemotherapy plus natural IFN-alpha or recombinant IFN alpha-2a.
• To assess treatment-related toxicities and antibody development associated with IFN-alpha use.

Main Methods:

• A randomized trial involving patients with any stage of small cell lung cancer.
• Three arms: chemotherapy (cisplatin and etoposide) alone, chemotherapy + natural IFN-alpha, and chemotherapy + recombinant IFN alpha-2a.
• IFN-alpha was administered from the first day of treatment, three times a week intramuscularly.

Main Results:

• No significant difference in median survival was observed between the three arms (10.2, 10.0, and 10.1 months, respectively).
• Two-year survival rates were 15% (chemotherapy alone), 3% (chemotherapy + natural IFN-alpha), and 11% (chemotherapy + recombinant IFN alpha-2a).
• Higher incidence of Grade 3 and 4 leukopenia in IFN-alpha arms led to dose reductions; antibodies to recombinant IFN occasionally developed.

Conclusions:

• Concomitant administration of IFN-alpha with chemotherapy in SCLC did not improve survival outcomes.
• IFN-alpha use was associated with increased leukopenia and potential antibody formation.
• IFN-alpha might be more appropriate as maintenance therapy rather than induction therapy to allow for optimal chemotherapy dosing.